secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2025-12-02T23:59:59+00:00
Accession:  0001434647-25-000015
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra appoints Alicia Secor to board; director Wendy Dixon retires
------------------------------------------------------------------

- Director Wendy Dixon resigned effective Dec 2, 2025; no disagreement with company operations.
- Alicia Secor appointed to board as Class I director, term expiring at 2028 annual meeting.
- Secor will serve on Compensation and Audit committees; compensation per director policy.
- Secor brings 30+ years life sciences experience, including CEO roles at Atalanta and Juniper.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143464725000015/0001434647-25-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143464725000015/zvra-20251126.htm
  HTML page:      https://secwatch.observer/filing/0001434647-25-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer